BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA Indication
BeiGene, a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) for…
Read More...
Read More...